Detection of CDX2 expression

Details Detection of CDX2 expression Detection of CDX2 expression

2005-02-16

2009-02-03

Yu, Misook (Department: 1642)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C436S064000

Reexamination Certificate

active

07485422

ABSTRACT:
Screening and diagnostic reagents, kits and methods for metastatic colorectal cancer or primary and/or metastatic stomach or esophageal cancer are disclosed. Vaccines compositions and methods of for treating and preventing metastatic colorectal cancer or primary and/or metastatic stomach or esophageal cancer are disclosed.

REFERENCES:
patent: 5518888 (1996-05-01), Waldman et al.
patent: 5601990 (1997-02-01), Waldman
patent: 5731159 (1998-03-01), Waldman et al.
patent: 5879656 (1999-03-01), Waldman
patent: 6130043 (2000-10-01), Billing-Medel et al.
patent: 2001/0039016 (2001-11-01), Waldman et al.
patent: 98/09510 (1998-03-01), None
patent: WO 00/20640 (2000-04-01), None
Bai et al (Cancer Lett Feb. 8, 2002;176(1):47-55, abstract only).
Makino et al., “p53 as an indicators of lymph node metastases in invasive early colorectal cancer,”Anticancer Research(2000) 20(38):2000-2005.
Wiltz et al., “Expression of enzymatically active sucrase isomaltase is a ubiquitous property of colon adenocarcinomas,”Gastroenterology(1991) 100(5):1266-1278.
Lise et al., “Association between sucrase-isomaltase and p53 expression in colorectal cancer,”Annals of Surgical Oncology(1997) 4(2):176-183.
Zweibaum et al., “Sucrase iso maltase a marker of fetal and malignant epithelial cells of the human colon,”International Journal of Cancer(1983) 32(4):407-412.
Jessup et al., “Sucrase-isomaltase is an independent prognostic marker for colorectal carcinoma,”Diseases of the Colon and Rectum(1995) 38(12):1257-1264.
Di Guglielmo et al., “Nucleotide requirements for CDX2 binding to the cis promoter element mediating intestine-specific expression of guanylyl cyclase C,”FEBS Letters(2001) 507(2):128-132.
Supplementary European Search Report dated Aug. 11, 2005 for European Application No. 01922785.
Cagir, B., et al., “Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer,”Am. Soc. Internal Med.,1999, 131(11), 805-812.
Li,Z., et al., “Peptide-regulated guanylate cyclase pathways in rat colon: in situ localization of GCA, GCC, and guanylin mRNA,”Am. Physiological Soc.,1993, G394-G402.
London, R.M., et al., “Signal transduction pathways via guanylin and uroguanylin in stomach and intestine,”Am. Physiological Soc.,1997, G93-G105.
Mallo, G.V., et al., “Expression of theCdxlandCdx2homeotic genes leads to reduced malignancy in colon cancer-derived cells,”J. Biological Chem.,1998, 273(22), 14030-14036.
Mallo, G.V., et al., “Molecular cloning, sequencing and expression of the mRNA encloding human Cdx1 and Cdx2 homeobox. Down-regulation of Cdx1 and Cdx2 mRNA expression during colorectal carcinogenesis,”Int. J. Cancer(Pred. Oncol), 1997, 74, 35-44.
Wu, G.D., et al., “Sucrase-isomaltase gene expression in barrett's esophagus and adenocarcinoma,”Gastroenterology,1993, 105, 837-884.
Iannettoni, M.D. et al., “Detection of Barrett's adenocarcinoma of the gastric cardia with sucrase isomaltase and p53”,Ann. Thorac. Surg.,1996, 62, 1460-1466.

Affiliated with

Also associated with

Rating

Detection of CDX2 expression does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Detection of CDX2 expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Detection of CDX2 expression will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4128996